Paloma Partners’s Sarepta Therapeutics SRPT Stock Holding History

Paloma Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,900	Closed	-$266K	–	2189
2020 Q3	$266K	Buy	+1,900	New	+$289K	0.01%	1567

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Paloma Partners's SRPT Position: Q3 2019 in Review

Paloma Partners sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 2,054 shares — an estimated $312K sold.

Paloma Partners first reported a position in SRPT in Q3 2013 and held it in 9 quarters. The position peaked at $23.5M in Q2 2018. 340 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

Paloma Partners reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
Paloma Partners sold 2,054 Sarepta Therapeutics shares in Q3 2019, an estimated $312K.
Paloma Partners first reported a position in Sarepta Therapeutics in Q3 2013 and held it in 9 quarters.
Paloma Partners's Sarepta Therapeutics position peaked at $23.5M in Q2 2018.
340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.